Form 4: Intellia Therapeutics CEO John Leonard Reports Changes in Beneficial Ownership

Intellia Therapeutics' CEO, John M. Leonard, reports acquisition of restricted stock units and stock options, along with adjustments to shares held by a trust.

Summary

• On March 1, 2024, John M. Leonard, CEO of Intellia Therapeutics, reported changes in his beneficial ownership of the company's stock.
• Leonard acquired 113,586 shares of common stock through restricted stock units.
• He also acquired options to purchase 163,929 shares of common stock at an exercise price of $32.66, vesting in installments starting January 1, 2025.
• Additionally, 58,415 shares held by the John M. Leonard 2015 Irrevocable Trust were disposed of.
• Following these transactions, Leonard directly owns 960,072 shares of Intellia common stock and 163,929 derivative securities.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting transactions. The grant of stock options and RSUs is generally a positive sign, but the disposal of shares by the trust introduces a slight element of uncertainty.

Positives

• The grant of restricted stock units and stock options to the CEO aligns his interests with those of the shareholders.
• The vesting schedule of the stock options incentivizes long-term performance.

Negatives

• The disposal of shares held by the trust could be perceived negatively, although the reason for the disposal is not disclosed.

Risks

• The value of the stock options is dependent on the future performance of Intellia Therapeutics' stock price.
• Changes in beneficial ownership by key executives can sometimes create uncertainty in the market.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the stock options suggests a long-term commitment from the CEO.

Industry Context

Changes in beneficial ownership are a routine part of executive compensation and are closely watched by investors for insights into management's confidence in the company's prospects. This filing is standard for reporting such changes to the SEC.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules are typically structured to incentivize long-term performance and retention.
• Companies like CRISPR Therapeutics and Editas Medicine also utilize stock options and restricted stock units as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign of alignment between management and shareholder interests.
• Employees may see the CEO's increased stake in the company as a sign of confidence in its future prospects.

Key Dates